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Objective: This retrospective review examines periprocedural morbidity and early functional responses to primary renal
artery angioplasty and stenting (RA-PTAS) for patients with atherosclerotic renovascular disease (RVD).
Methods: Consecutive patients undergoing primary RA-PTAS for hemodynamically significant atherosclerotic RVD with
hypertension and/or ischemic nephropathy were identified from a prospectively maintained registry. Hypertension
responses were determined based on pre- and post-intervention blood pressure measurements and medication require-
ments. Estimated glomerular filtration rate (eGFR) was used to determine renal function responses. Both hypertension
and renal function responses were assessed at least three weeks after RA-PTAS. Stepwise multivariable regression analysis
was used to examine associations between blood pressure and renal function responses to RA-PTAS and select clinical
variables.
Results: One-hundred ten primary RA-PTAS were performed on 99 patients with atherosclerotic RVD with a mean
angiographic diameter-reducing stenosis of 79.2  12.9%. All patients had hypertension (mean of 3.4  1.3 antihyper-
tensive agents). Mean pre-intervention eGFR was 49.9 22.7 mL/min/1.73 m2, and 74 patients had a pre-intervention
eGFR< 60mL/min/1.73 m2. The technical success rate for RA-PTAS was 94.5%. The periprocedural complication rate
was 5.5%; there were no periprocedural deaths. Statistically significant decreases inmean systolic blood pressure (161.3 25.2
vs. 148.5  25.2 post-intervention, P < .0001), diastolic blood pressure (78.6  13.3 versus 72.5  13.5 post-
intervention, P< .0001), and number of antihypertensive agents (3.3 1.2 versus 3.1 1.3 post-intervention, P .009)
were observed. Assessed categorically, hypertension response to RA-PTAS was cured in 1.1%, improved in 20.5%, and
unchanged in 78.4%. Categorical eGFR response to RA-PTAS was improved in 27.7%, unchanged in 65.1%, and
worsened in 7.2%. Multivariable stepwise regression revealed associations between pre- and post-intervention systolic
blood pressure (P < .0001), diastolic blood pressure (P < .0001), and eGFR (P < .0001), as well as a trend toward
improved diastolic blood pressure response among patients managed with staged bilateral intervention (P  .0589).
Conclusion: Primary RA-PTAS for atherosclerotic RVDwas associated with low peri-procedural morbidity and mortality
but only modest early improvements in blood pressure and renal function. Results from ongoing prospective trials are
needed to assess the long term outcomes associated with RA-PTAS and clarify its role in the management of
atherosclerotic RVD. (J Vasc Surg 2008;48:580-88.)Severe secondary hypertension and ischemic nephrop-
athy due to atherosclerotic renovascular disease (RVD) are
associated with increased risk for both adverse cardiovascu-
lar events and all-cause mortality.1-4 Medical management
of hypertension, hyperlipidemia, and associated risk factors
is appropriate initial management of atherosclerotic RVD,
but some patients exhibit uncontrolled hypertension
and/or progressive decline in renal function despite medi-
cal therapy. Although several retrospective cohort series
have reported favorable blood pressure and renal function
outcomes associated with RA-PTAS,5 randomized trials
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580published to date have been heterogeneous in terms of
their procedural management and have reported mixed
results that do not uniformly favor endovascular manage-
ment of RVD.6-8 In spite of the limitations of existing
evidence, percutaneous renal artery angioplasty and stent-
ing (RA-PTAS) has become the most commonly utilized
form of management for patients with atherosclerotic RVD
requiring procedural intervention. Correspondingly, the
frequency with which this procedure is performed in the
United States has risen dramatically in recent years.9,10
Increasing utilization of RA-PTAS has been accompanied
by scrutiny of the evidence supporting its role in the man-
agement of atherosclerotic RVD. A comparative effective-
ness review by the Agency for Healthcare Research and
Quality concluded that there was insufficient evidence to
support one treatment approach over another,11 prompt-
ing the Centers for Medicare and Medicaid Services to
examine application of this procedure through both a na-
tional coverage analysis and an evidence development and
coverage advisory committee.12,13
While eagerly awaiting the results of ongoing clinical
trials evaluating RA-PTAS,14 this retrospective report de-
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this retrospective study were: 1) to examine the periproce-
dural morbidity and mortality associated with primary RA-
PTAS for atherosclerotic RVD; 2) to evaluate early blood
pressure and renal function responses to RA-PTAS; and 3)
to examine clinical and anatomic factors associated with
procedural outcomes. Based on previous investigations, we
hypothesized that completeness of repair (ie, treatment of
all hemodynamically significant disease), increased pre-
intervention serum creatinine, employment of distal renal
artery balloon occlusion, and use of antiplatelet medica-
tions would influence blood pressure and/or renal function
responses in a favorable fashion.15-17
METHODS
Study population
This retrospective investigation was conducted with
approval from the Wake Forest University Health Sciences
Institutional Review Board. Consecutive patients undergo-
ing primary RA-PTAS for hemodynamically significant ath-
erosclerotic renovascular disease (defined pre-intervention
as60% diameter-reducing stenosis by duplex ultrasonog-
raphy) performed by vascular surgeons at the Wake Forest
University Baptist Medical Center from October 2003
through September 2007 were identified from a prospec-
tively maintained database. All treated patients had hyper-
tension with or without associated ischemic nephropathy.
RA-PTAS performed for fibromuscular dysplasia or recur-
rent renal artery stenosis were excluded from analysis.
Interventional management
All RA-PTAS were performed in an endovascular oper-
ating suite as previously described.18 All patients under-
went pre-intervention intravenous hydration with normal
saline (patients with pre-intervention eGFR  30 mL/
min/1.73 m2) or sodium bicarbonate (patients with pre-
intervention eGFR  30 mL/min/1.73 m2) and received
four 600 mg doses of N-acetylcysteine every twelve hours
beginning 24 hours before RA-PTAS. Patients with bilat-
eral RAS were managed according to clinical response to
unilateral RA-PTAS (improved blood pressure control
and/or eGFR). When logistically feasible within the overall
clinical plan of care, patients requiring intervention for
bilateral renal artery lesions were managed in a staged
fashion to minimize contrast volume per procedure and to
reduce the potential for bilateral ischemic renal complica-
tions.
Procedures were performed using percutaneous femo-
ral or open brachial 6F sheath access followed by systemic
heparin anticoagulation. Iodixanol (Visipaque, Amersham
Health, Princeton, NJ) diluted 1:1 with normal saline was
the arterial contrast medium of choice, and carbon dioxide
utilized as an alternative or adjunct in the setting of severely
compromised renal function and/or history of allergy to
iodinated contrast media. Renal artery cannulation was
performed using a minimal contact technique, with ostial
engagement using an angled guide catheter. Lesion predi-lation prior to angioplasty and stenting was performed at
the discretion of the operating surgeon. RA-PTAS were
performed with balloon-mounted stents sized to match the
renal artery distal to the stenotic lesion. Stents were posi-
tioned to completely cover the stenoses and, in the setting
of ostial lesions, to extend 1-2 mm into the aortic lumen
following deployment.
When distal renal artery balloon occlusion was utilized
as a protective measure prior to RA-PTAS, initial crossing
of the stenotic renal artery lesion was performed with a
commercially available 0.014” balloon-tipped guidewire
(Guardwire, Medtronic, Minneapolis, Minn). After passing
the stenotic lesion, the distal occlusion balloon was inflated
and distal renal artery occlusion confirmed by hand injec-
tion of contrast. Following RA-PTAS, the static column of
blood between the treated lesion and occlusion balloon was
evacuated using a rapid exchange catheter (Export Cathe-
ter,Medtronic,Minneapolis,Minn). After aspirating 40-60
ml of blood, the renal artery was then irrigated with 20-60
ml of heparinized saline prior to deflation of the occlusion
balloon and completion angiography.
Patients were routinely treated with pre-operative aspi-
rin and discharged within 24 hours following RA-PTAS on
combinationoral antiplatelet therapy (aspirin plus clopi-
dogrel). Post-intervention outpatient follow up (including
clinical evaluation, renal artery duplex ultrasound, blood
pressure measurement, and serum creatinine) was routinely
performed at four weeks, six months, and then annually.
Data collection and management
Data were collected from the hospital, outpatient
clinic, and clinical vascular laboratory records. Electroni-
cally archived renal angiography images were measured
using computer software, and percent renal artery stenosis
by angiography was determined by measuring the smallest
luminal diameter of the point of maximal stenosis and
comparing it with the lumen of the distal main renal artery.
Blood pressure and renal function outcomes were assessed
based on the first post-intervention data available at three
or more weeks following RA-PTAS in order to minimize
the influences of peri-procedural contrast administration
and intravascular volume expansion.
Bilateral brachial systolic and diastolic blood pressures
were recorded in the outpatient Vascular Clinic with pa-
tients in the seated position using an oscillometer (Vital
Signs 300, Welch Allyn, Beaverton, Ore). Measured blood
pressures from the outpatient visit prior to RA-PTAS and
the first outpatient follow up visit three or more weeks
following RA-PTAS were used for evaluation of early blood
pressure response to intervention. Categorical hyperten-
sion response to RA-PTAS was graded as cured, improved,
or failed using a combination of blood pressure and num-
ber of antihypertensive agents required for hypertension
management before versus after intervention as previously
described.19 Patients’ self-reported highest known blood
pressure was also recorded as a descriptive indicator of
hypertension severity, but only measured blood pressure
was used to evaluate clinical response to RA-PTAS. History
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tient hospitalization for management of severe hyperten-
sion associated with target organ damage including pulmo-
nary edema, hypertensive encephalopathy, acute coronary
syndrome, and acute renal failure.20
Estimated glomerular filtration rate (eGFR) was calcu-
lated using the abbreviated Modification of Diet in Renal
Disease formula:21 eGFR/1.73 m2  186  (Serum Cre-
atinine)1.154 (Age)0.203 (0.742 if female) (1.210
if African American). Post-intervention renal function was
categorized as improved or worsened based on a 20%
increase or decrease in eGFR, respectively, and otherwise
categorized as unchanged.
Preoperative identification of hemodynamically signif-
icant renal artery stenosis was performed with duplex ultra-
sound using previously described criteria.22 Procedural
technical success was defined as RA-PTAS of the intended
lesion with a residual diameter-reducing stenosis of 30%
on completion angiography and absence of hemodynami-
cally significant stenosis defined as main renal artery peak
systolic velocity 180 cm/s on completion renal duplex
ultrasonography. Staged bilateral RA-PTAS were treated as
a single intervention for analysis of blood pressure and renal
function outcomes, while both staged RA-PTAS proce-
dures were analyzed individually for description of procedure-
related technical success and complications. Distal renal
artery balloon occlusion during RA-PTAS was defined as
complete if no distal flow was identifiable on post-inflation
angiography, incomplete if ongoing branch or accessory
renal artery flow was observed, and failed if no significant
renal artery occlusion was achieved. Treatment of renal
artery stenosis was considered complete in patients with
duplex-defined hemodynamically significant unilateral dis-
ease undergoing unilateral repair or patients with bilateral
disease undergoing bilateral RA-PTAS, and incomplete in
patients with bilateral disease treated with unilateral
RA-PTAS. Peri-procedural complications were defined as
procedure-related complications occurring within the first
30 days following RA-PTAS.
Statistical methods
Descriptive statistics are reported as mean  standard
deviation for continuous measures and count (percent) for
categorical factors. Blood pressure, antihypertensive agent,
and renal function outcomes following RA-PTAS were
assessed with paired t tests; an alpha level of .05 was
considered statistically significant. Associations between
clinical or procedural predictors of blood pressure and
eGFR response to RA-PTAS were examined using multi-
variable linear regression models. A “best” model for each
outcome was selected using a stepwise selection approach
where candidate variables with P-values.10 were entered
one at a time in order of descending significance and
retained if they remained significant in the multivariable
model at the .10 level following entry. Model residuals
were examined after the selection process to evaluate fit and
examine influential observations. All statistical analyseswere performed using SAS software, version 9 (SAS Insti-
tute, Cary, NC).
RESULTS
From October 2003 through September 2007, 144
RA-PTAS were performed on 133 patients by the Vascular
and Endovascular Surgery Section at our center. One-
hundred ten primary RA-PTAS procedures performed for
atherosclerotic renovascular disease on 99 of these patients
form the basis this report (Table I). Mean patient age was
69 10 years (range, 40-88 years). Of the patients, 87.9%
Table I. Descriptive statistics for patients undergoing
primary renal artery angioplasty and stenting (N  99)
N (%) Mean  SD
Age (years) 69.1  10.0
Caucasian race 87 (87.9)
Female gender 51 (51.5)
Weight (kg) 76.1  15.4
Highest known SBP (mm Hg)
†
201.3  28.3
Highest known DBP (mm Hg)
†
101.7  22.2
Renal artery PSV (cm/s) 268.3  99.6
Significant contralateral RAS* 33 (41.8)
Antihypertensive agents 3.4  1.
Serum creatinine (mg/dL) 1.5  0.6
eGFR** (mL/min/1.73 m2) 49.9  22.7
Renal insufficiency (eGFR)
None (eGFR  60) 25 (25.3)
Moderate (eGFR 30-60) 59 (59.6)
Severe (eGFR  30) 15 (15.2)
Ischemic nephropathy (Cr  1.8) 34 (34.3)
Diabetes 30 (30.3)
Any cerebrovascular disease 31 (31.3)
Stroke 27 (27.3)
TIA 4 (4.0)
Any cardiac disease 60 (60.6)
Coronary artery disease 44 (44.4)
Angina 5 (5.1)
Coronary intervention 26 (26.3)
LVH 35 (35.4)
COPD 14 (14.1)
Smoking
Current 25 (25.2)
Former 46 (46.5)
Hypertensive emergency 14 (14.1)
Resistive Index** 0.75  0.08
Resistive Index  0.8** 23 (24.7)
Abdominal aortic aneurysm 6 (6.1)
Preoperative medications
Aspirin 68 (68.7)
Clopidogrel 24 (24.2)
Statin 58 (58.6)
Fibrate 5 (5.1)
COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pres-
sure; eGFR, estimated glomerular filtration rate; LVH, left ventricular hy-
pertrophy; PSV, peak systolic velocity; RAS, renal artery stenosis; SBP,
systolic blood pressure; TIA, transient ischemic attack.
*Significant contralateral renal artery stenosis defined as peak systolic veloc-
ity 180 cm/s on preoperative duplex ultrasound.
**Resistive Index from the side with the higher B-Segment primary renal
artery angioplasty and stenting.
†Highest known blood pressure values prior to intervention.were Caucasian, and 51.5% were female. All patients had
nomin
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26.0/78.3  13.1) and were on a mean of 3.4  1.3
antihypertensive medications prior to intervention. Four-
teen patients (14.1%) had a previous inpatient hospitaliza-
tion for management of a hypertensive emergency. Mean
serum creatinine was 1.5  0.6 mg/dL (range, 0.6-3.6
mg/dL) and mean eGFR was 49.9  22.7 mL/min/1.73
m2 (range, 15.8-152.2 mL/min/1.73 m2). Seventy-four
patients (74.7%) had a pre-intervention eGFR  60 mL/
min/1.73 m2. No patients were dialysis dependent prior to
intervention. Comorbid conditions included coronary ar-
tery disease (44.4%), cerebrovascular disease (31.3%), and
diabetes (30.3%). Among patients with two kidneys, 33
(42%) had bilateral, hemodynamically significant renal ar-
tery stenosis by pre-intervention duplex ultrasound. Of the
99 patients, 74 were taking antiplatelet agents at the time of
initial evaluation for RA-PTAS, including aspirin alone in
50 patients, clopidogrel alone in six patients, and aspirin
plus clopidogrel in 18 patients.
Table II summarizes procedural data (N  110). The
technical success rate for RA-PTAS was 94.5%. Six techni-
cal failures occurred in five patients and were related to
inability to establish ostial engagement in one case, and a
residual post-intervention stenosis in five cases. All patients
designated as technical failures due to residual stenosis were
identified by completion duplex ultrasonography; in con-
trast, completion angiography identified residual stenosis
greater than 10% in only three patients, none of whom had
residual lesions 30% by angiography. Prior to RA-PTAS
the mean diameter-reducing renal artery stenosis was
79.2  12.9%, and stents were placed in 108 procedures
(98.1%). Eighty-six (86.9%) RA-PTAS were unilateral,
while 11 (11.1%) of 99 were staged bilateral interventions;
two patients (2.0%) underwent bilateral RA-PTAS at the
same procedural setting. Renal artery stenosis was treated in
an incomplete fashion (unilateral intervention in the setting
of bilateral disease) in 21 patients (21.2%) and a complete
Table II. Descriptive statistics for RA-PTAS procedures (
N (%)
Pre-intervention stenosis (%)
Renal artery diameter (mm)
Stent diameter (mm)
Stent length (mm)
Renal stent/artery diameter ratio (%)
Stent placed 108 (99.1)
Predilation prior to stenting 14 (12.7)
Distal Protection
Attempted 100 (90.9)
Complete (% of attempted) 74 (74.0)
Partial (% of attempted) 22 (22.0)
Failed (% of attempted) 4 (4.0)
Balloon occlusion time (minutes)
Staged treatment of bilateral RAS* 11 (11.1)
Contrast volume (mL)
Fluoroscopy time (minutes)
*RAS, renal artery stenosis defined as peak systolic velocity 180 cm/s: defashion in 73 patients (73.7%); five patients whose con-tralateral renal artery was not adequately assessed on pre-
intervention duplex ultrasound due to technical limitations
could not be categorized in terms of completeness of
treatment. Fifteen patients had RA-PTAS performed to a
single functioning kidney with either contralateral renal
artery occlusion or previous nephrectomy. A mean volume
of 58.4  34.1 mL of arterial contrast was used per proce-
dure, and mean fluoroscopy time was 9.5  7.3 minutes.
One hundred RA-PTAS (90.9%) had distal renal artery
balloon occlusion attempted for protection from procedure-
related atheroembolism. Among these, renal artery occlu-
sion was complete in 74, partial in 22, and failed in four.
There were no peri-procedural deaths. Peri-procedural
complications were associated with six out of 110 proce-
dures (5.5%). Four of six peri-procedural complications
were access site-related: one retroperitoneal hematoma,
one inguinal hematoma associated with hypotension, one
brachial hematoma, and one femoral artery pseudoaneu-
rysm. One peri-procedural myocardial infarction occurred
in a patient who required coronary artery bypass and sub-
sequently developed acute renal failure requiring hemodi-
alysis. An additional patient experienced post-intervention
hypotension attributed to a protamine reaction and re-
quired overnight observation in the intensive care unit.
Table III shows mean blood pressure and renal func-
tion responses following RA-PTAS. Eighty-eight patients
had post-intervention blood pressure data and 83 patients
had serum creatinine data available for analysis at three or
more weeks following RA-PTAS, and the median interval
between intervention and early follow up was 9.4 weeks.
Statistically significant decreases in mean systolic blood
pressure (161.3  25.2 pre-versus 148.5  25.2 post-
intervention, P .0001), diastolic blood pressure (78.6
13.3 pre-versus 72.5  13.5 post-intervention, P 
.0001), and number of antihypertensive agents (3.3  1.2
pre-versus 3.1  1.3 post-intervention, P  .009) were
observed. Categorical hypertension response to RA-PTAS
10)
Mean  SD Minimum Maximum
79.2  12.9 55.0 98.0
5.6  1.3 3.3 8.8
5.7  0.8 4.0 7.0
16.2  3.1 12.0 24.0
105.7  21.5 69.0 181.8
15.1  5.9 8.0 35.0
58.4  34.1 9.0 156.0
9.5  7.3 2.7 41.6
ator for staged treatment is 99 (complete procedures).N1was cured in one patient (1.1%), improved in 18 (20.5%),
ere a
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from 1.6  0.6 pre-intervention to 1.5  0.6 post-
intervention (P  .0113). A corresponding statistically
significant increase in eGFR was also observed (46.8 
17.3 pre-intervention versus 50.2 19.7 post-intervention
P  .0114). Based on a 20% change in eGFR, renal
function was improved in 27.7%, unchanged in 65.1%, and
worsened in 7.2%. Unadjusted percent changes in systolic
blood pressure, diastolic blood pressure, and eGFR relative
to pre-intervention values stratified by complete versus
incomplete treatment are shown in the Figure. Among
patients undergoing complete repair, post-intervention in-
creases in eGFRwere11.8% for patients with two kidneys
and unilateral stenosis, 7.4% among patients with bilat-
eral disease undergoing bilateral intervention, and 2.6%
for patients with stenosis affecting their single functioning
kidney.
Multivariable linear regression models derived using
Fig. Mean percent change in outcome variables following RA-
PTAS: complete versus incomplete treatment. Unadjusted data
displayed for patients with post-intervention blood pressure (N 
88) and serum creatinine (N  83) data available at 3 weeks
following RA-PTAS. SBP, systolic blood pressure (mmHg); DBP,
diastolic blood pressure (mmHg); eGFR, estimated glomerular
filtration rate as calculated using abbreviated Modification of Diet
in Renal Disease formula. Incomplete treatment is defined as
unilateral intervention in the setting of bilateral hemodynamically
significant renal artery stenosis as determined by pre-intervention
duplex ultrasound.
Table III. Renal function and blood pressure responses fo
Pre-intervention*
Blood pressure
Systolic (mmHg) 161.3  25.2
Diastolic (mmHg) 78.6  13.3
Antihypertensive agents 3.3  1.2
Renal function
Serum creatinine (mg/dL) 1.6  0.6
eGFR (mL/min/1.73 m2) 46.8  17.3
Post-intervention measures assessed at a minimum of three weeks following
*Pre-operative values from patients on whom paired post-operative values w
**P value from paired samples t-test.stepwise selection are summarized in Table IV. We ob-served a significant positive association between post-
intervention systolic blood pressure and pre-intervention
systolic blood pressure (P  .0001). A similar positive
association with pre-intervention values was observed for
diastolic blood pressure (P  .0001), while a trend toward
lower diastolic blood pressure was associated with staged
bilateral repair status (as opposed to unilateral repair or
bilateral repair in a single procedural setting) (P  .0589).
A significant positive association between pre-intervention
eGFR and post-intervention eGFR was also observed (P
.0001). All covariates assessed are included in Tables I
and II.
DISCUSSION
Primary RA-PTAS for atherosclerotic RVD was associ-
ated with no peri-procedural mortality, a low incidence of
complications, and early improvements in blood pressure
and renal function in this retrospective series of patients
treated at our center. While these improvements in blood
pressure and renal function following RA-PTAS were sta-
tistically significant when considered as continuous mea-
sures, the magnitude of the observed changes was generally
modest. The clinical relevance of these early changes ap-
peared limited when assessed in a categorical fashion: cure
or improvement of hypertension was achieved in a minority
of patients (1% and 21%, respectively) and eGFR improved
in 28% of patients when defined by an increase of 20% of
pre-intervention eGFR. Apart from pre-intervention mea-
sures of outcome variables (SBP, DBP, or eGFR, respec-
tively), an association between staged bilateral intervention
and improved post-intervention diastolic blood pressure
was the only other significant relationship we observed
between clinical and/or procedural factors and functional
outcomes using stepwise selection. Stepwise selection
therefore produced either simple (for SBP and eGFR) or
bivariate (for DBP) linear models. Contrary to earlier ob-
servations, we did not identify an association between
aspirin use and post-intervention eGFR response in this
study,16 although our ability to identify such an association
may have been impaired by a relative paucity of patients
(25%) not taking an antiplatelet medication preopera-
tively. Otherwise, these results are consistent with prior
ing RA-PTAS
Post-intervention Difference P**
148.5  25.2 12.8 0.0001
72.5  13.5 6.1 0.0001
3.1  1.3 0.2 0.0090
1.5  0.6 0.08 0.0113
50.2  19.7 3.5 0.0114
vention. Median follow-up  9.4 weeks post-intervention.
lso available.llow
interRA-PTAS results reported by our group.16,18
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early diastolic blood pressure response to RA-PTAS is
consistent with other results observed after open renal
artery revascularization.17 This observed association be-
tween staged bilateral intervention and improved blood
pressure response may be related to complete treatment in
all patients managed in this fashion; conversely, residual
contralateral disease in patients undergoing unilateral inter-
vention could potentially impair blood pressure responses.
Fig 1 displays mean percent change in post-intervention
measures stratified by complete (ie, treatment of all hemo-
dynamically significant disease identified on pre-intervention
duplex ultrasonography) versus incomplete treatment.
While a mean improvement in both groups was observed
for both systolic and diastolic blood pressures, postopera-
tive mean eGFR was increased by mean of 9.7 mL/min/
1.73 m2 in the complete treatment group versus a mean
decrease of decrease of 2.8 mL/min/1.73 m2 among
patients treated in an incomplete fashion. Such incomplete
treatment is not an uncommon occurrence in our current
management algorithm; following initial intervention, a
contralateral procedure may not be performed if hyperten-
sion and/or ischemic nephropathy prompting the first
procedure have improved.
Distal renal artery balloon occlusion at the initiation of
RA-PTAS was attempted in the majority of patients
(90.9%) and produced complete renal artery occlusion
distal to the stenotic lesion in 74% of attempts. Incomplete
balloon occlusion of arterial flow was most often attribut-
able to either ongoing renal perfusion through branch
vessels (either unprotected accessory renal arteries or main
renal artery branches with proximal origins) or size mis-
match between the fully inflated balloon and renal artery.
These cases reflect size limitations of currently available
balloon occlusion devices when renal artery diameter ex-
ceeds 6 mm. The commercially available device we cur-
rently utilize for balloon occlusion “off label” under an
investigational device exemption from the United States
Food and Drug administration was originally designed for
use in coronary saphenous vein grafts, and currently avail-
able filter protection devices are also susceptible to similar
size mismatch issues when used in the renal circulation. It is
therefore possible that technical success rates with balloon
occlusion during RA-PTAS might improve if renal-specific
devices compatible with larger diameter distal vessels be-
Table IV. Multivariable linear regression models derived
Outcome Variable
Postoperative SBP Preoperative SBP
Postoperative DBP Preoperative DBP
Staged bilateral intervention
Postoperative eGFR Preoperative eGFR
DBP, diastolic blood pressure, mm Hg; eGFR, estimated glomerular filtrati
All candidate covariates included within Tables I and II.
All estimates are per single unit change in each variable.come available in the future. Nonetheless, the 7% frequencyof worsened post-intervention eGFR in this study com-
pares favorably with functional deterioration rates ranging
from 8-27% in retrospective series of RA-PTAS5,23-27 per-
formed without distal renal artery balloon occlusion and is
consistent with other reports uniformly employing distal
protection.18,28-31 We did not detect an association be-
tween either use or completeness of protective distal renal
artery balloon occlusion and eGFR response to RA-PTAS,
but our power to detect such an effect was limited by the
small proportion of patients managed without balloon oc-
clusion (9.1%). Use of distal renal artery balloon occlusion
did not appreciably impact morbidity rates in this study
group, and no observed complications were directly attrib-
utable to use of the balloon occlusion device. A prospective
trial designed to evaluate the utility of renal artery balloon
occlusion during RA-PTAS is currently enrolling at our
center and will provide data that may define the utility of
balloon occlusion for embolic protection.
Renal artery revascularization using open operative
techniques in our center has been associated with cure of
hypertension in 10-12% of patients and improvement in
70-85%; renal function improvement was noted in 45-55%
of patients compared with a 5-15% incidence of de-
cline.15,17,32,33 Although RA-PTAS has not duplicated
these functional results in a durable fashion to date, it is
important to note that the no peri-procedural deaths oc-
curred in this cohort (vs reported perioperative mortality
rates of 2-8% in large series of open repair15,17,32). This
lower procedure-associated mortality makes RA-PTAS an
attractive method for renal artery intervention in patients
who would be considered high risk for open revasculariza-
tion, and it is our perception that we do offer RA-PTAS to
some patients who would not be offered open renal artery
repair. Compared with our center’s previous report on a
cohort undergoing open renal artery revascularization for
atherosclerotic RVD,15 the current series of patients had
higher prevalence of diabetes, lower prevalence of ischemic
nephropathy, and a greater frequency of incomplete treat-
ment of RVD. These factors may have contributed the
comparatively reduced blood pressure and renal function
response rates following RA-PTAS. However, the 5.5%
incidence of complications in this series of RA-PTAS com-
pares favorably with morbidity associated with open renal
revascularization in terms of both incidence (15-30% with
open management) and severity (2/3 of complications in
stepwise selection
Estimate Standard error P
0.406 0.099 0.0001
0.604 0.089 0.0001
7.06 3.687 0.0589
0.904 0.077 0.0001
e, mL/min/1.73 m2; SBP, systolic blood pressure, mm Hg.using
on ratthe current series were access-site related). While modest
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have been demonstrated in most recent series, retrospective
comparisons have not demonstrated a survival benefit asso-
ciated with RA-PTAS.34 RA-PTAS appears to provide less
robust blood pressure and renal function responses than
open revascularization but lower risk for post-procedure
death or complications. Recent trends in relative frequency
of RA-PTAS and open operative repair indicate that the
majority of patients and providers find this trade accept-
able.9,10 Ultimately, the value of endovascular renal artery
repair will require analysis of long-term adverse events and
dialysis-free survival relative to the natural history of med-
ically treated RVD.
Benefits of endovascular treatment over the natural
disease history in patients who cannot be managed medi-
cally are presumed by those utilizing RA-PTAS but remain
to be proven. Results from several randomized trials com-
paring RA-PTASwithmedical management are expected in
the near future and may help to answer this question in the
context of current medical therapy. The Angioplasty and
Stent for Renal Artery Lesions (ASTRAL) trial is a multi-
center, randomized trial of primary renal artery revascular-
ization versus medical management designed to evaluate
the effects of RA-PTAS on the rate of renal dysfunction
progression; secondary endpoints include blood pressure
control, renal events, vascular events, and mortality.35 Ini-
tial results from ASTRAL are anticipated in 2008. The
Cardiovascular Outcomes in Renal Atherosclerotic Lesions
(CORAL) trial is an ongoing multicenter, randomized trial
evaluating the effects of RA-PTAS with distal embolic
protection in patients with systolic hypertension; the pri-
mary composite endpoint includes event-free survival from
a composite of cardiovascular and renal outcomes (cardio-
vascular or renal death, myocardial infarction, hospitaliza-
tion for congestive heart failure, stroke, doubling of serum
creatinine, and need for renal replacement therapy).14 The
Renal Atherosclerotic Revascularization Evaluation
(RAVE) study is a single center randomized trial designed
as a pilot study to compare renal revascularization with
medical therapy alone in patients with atherosclerotic renal
vascular disease in whom revascularization is indicated; the
primary endpoint for this study is a composite of death,
dialysis, and doubling of creatinine, with subsequent plans
for a larger multicenter trial designed based on the pilot
study outcomes. The Benefit of Stent Placement and Blood
Pressure and Lipid-lowering for the Prevention of Progres-
sion of Renal Dysfunction Caused by Atherosclerotic Ste-
nosis of the Renal Artery (STAR) study is a randomized trial
evaluating RA-PTAS in the setting of renal failure; this
study plans to randomize 140 participants with the primary
outcome of reduction in creatinine clearance at two and five
years.36 These studies and the results of other investigator-
initiated randomized clinical trials will help to clarify the
role of RA-PTAS.
This retrospective study has several limitations that
deserve discussion. Incomplete post-intervention renal
function and blood pressure data may have decreased our
ability to detect associations between covariates and theseoutcomes or introduced bias resulting in overestimation of
responses to RA-PTAS. Conversely, this study’s relatively
short follow-up interval (median interval of 9.4 weeks) may
have resulted in an underestimation of the ultimate re-
sponses to RA-PTAS due to assessment of post-intervention
outcomes earlier than the six month post-intervention in-
terval previously used by others for assessment of proce-
dural outcomes.6,8 Sensitivity for detecting early single
kidney changes in renal function and/or flow following
RA-PTAS likely would have been increased by routine use
of functional studies (such as nuclear medicine flow and
GFR scanning). While these studies are impractical for
routine clinical follow up due to cost, they are included as
components of post-intervention follow-up in the random-
ized clinical trial of distal balloon occlusion during
RA-PTAS being conducted at our institution. Blood pres-
sure response to RA-PTAS may have been better character-
ized using ambulatory blood pressure monitoring, but this
data was not obtainable given the retrospective nature of
this study. Finally, we were unable to reliably ascertain
patients’ medication compliance during clinic visits where
blood pressure measurements were obtained. We routinely
instruct patients anticipating renal artery duplex ultrasound
to be nothing prescribed orally (NPO) on the morning of
the study, but patients are also advised to take their blood
pressure medications. Conceivably, however, some patients
may have held their blood pressure medications prior to
clinic visits, especially when renal duplex ultrasonography
was planned on the same day. Because renal duplex ultra-
sounds were routinely performed at both pre-and post-
intervention visits, however, this phenomenon likely would
have introduced bias favoring the null hypothesis rather
than a type I error.
As ongoing assessment RA-PTAS continues, further
investigation should seek to improve functional responses
of percutaneous therapy while maintaining low complica-
tion rates. Active investigations into embolic protection,
drug-eluting stents, and medical management strategies all
have the potential to improve future RA-PTAS outcomes.
Results from ongoing prospective studies are needed to
evaluate the durability of endovascular treatment for ath-
erosclerotic renovascular disease, to establish the value of
distal renal artery balloon occlusion for protection from
atheroembolism, to assess outcomes following intervention
for recurrent disease and fibromuscular dysplasia, and to
identify predictors of both functional responses and disease
recurrence.
AUTHOR CONTRIBUTIONS
Conception and design: KH, MC, JP, JS, ME
Analysis and interpretation: MC, KH, JS, ME
Data collection: MC, JP, JS
Writing the article: MC, KH, JS, JP
Critical revision of the article: MC, KH, ME, JS
Final approval of the article: MC, KH, ME, JS, JP
Statistical analysis: JS, MC
Obtained funding: Not applicable
Overall responsibility: MC, KH
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 3 Corriere et al 587REFERENCES
1. Edwards MS, Craven TE, Burke GL, Dean RH, Hansen KJ. Renovas-
cular disease and the risk of adverse coronary events in the elderly: a
prospective, population-based study. Arch Intern Med 2005;165:
207-13.
2. Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal
RA, et al. Renal insufficiency as a predictor of cardiovascular outcomes
and mortality in elderly individuals. J Am Coll Cardiol 2003;41:
1364-72.
3. Johansson M, Herlitz H, Jensen G, Rundqvist B, Friberg P. Increased
cardiovascular mortality in hypertensive patients with renal artery ste-
nosis. Relation to sympathetic activation, renal function and treatment
regimens. J Hypertens 1999;17(12 Pt 1):1743-50.
4. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP,
et al. Cardiovascular disease risk status in elderly persons with renal
insufficiency. Kidney Int 2002;62:997-1004.
5. Leertouwer TC, Gussenhoven EJ, Bosch JL, van Jaarsveld BC, van Dijk
LC,Deinum J, et al. Stent placement for renal arterial stenosis: where do
we stand? A meta-analysis. Radiology 2000;216:78-85.
6. Plouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure outcome
of angioplasty in atherosclerotic renal artery stenosis - A randomized
trial. Hypertension 1998;31:823-9.
7. van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FHM, Deinum J,
Postma CT, et al. The effect of balloon angioplasty on hypertension in
atherosclerotic renal-artery stenosis. New England Journal of Medicine
2000;342:1007-14.
8. Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, Isles CG,
et al. Randomised comparison of percutaneous angioplasty vs continued
medical therapy for hypertensive patients with atheromatous renal ar-
tery stenosis. Journal of Human Hypertension 1998;12:329-35.
9. Knipp BS, Dimick JB, Eliason JL, Cowan JA, Henke PK, Proctor MS,
et al. Diffusion of new technology for the treatment of renovascular
hypertension in the United States: surgical revascularization versus
catheter-based therapy, 1988-2001. J Vasc Surg 2004;40:717-23.
10. Murphy TP, Soares G, Kim M. Increase in utilization of percutaneous
renal artery interventions by Medicare beneficiaries, 1996-2000. Amer-
ican Journal of Roentgenology 2004;183:561-8.
11. Balk E, Raman G, Chung M, Ip S, Tatsioni A, Alonso A, et al.
Effectiveness of management strategies for renal artery stenosis: a sys-
tematic review. Ann Intern Med 2006;145:901-12.
12. Centers for Medicare and Medicaid Services. NCA Tracking Sheet for
Percutaneous Transluminal Angioplasty (PTA) and Stenting of the
Renal Arteries (CAG-00085R4). 2007.
13. Centers for Medicare andMedicaid Services. Proposed DecisionMemo
for Percutaneous Transluminal Angioplasty (PTA) and Stenting of the
Renal Arteries (CAG-00085R4). 2007.
14. Cooper CJ, Murphy TP, Matsumoto A, Steffes M, Cohen DJ, Jaff M,
et al. Stent revascularization for the prevention of cardiovascular and
renal events among patients with renal artery stenosis and systolic
hypertension: rationale and design of the CORAL trial. Am Heart J
2006;152:59-66.
15. Cherr GS, Hansen KJ, Craven TE, Edwards MS, Ligush J, Jr., Levy PJ,
et al. Surgical management of atherosclerotic renovascular disease. J
Vasc Surg 2002;35:236-45.
16. Edwards MS, Corriere MA, Craven TE, Pan XM, Rapp JH, Pearce JD,
et al. Atheroembolism during percutaneous renal artery revasculariza-
tion. J Vasc Surg 2007;46:55-61.
17. Hansen KJ, Cherr GS, Craven TE, Motew SJ, Travis JA, Wong JM,
et al. Management of ischemic nephropathy: dialysis-free survival after
surgical repair. J Vasc Surg 2000;32:472-81.
timely fashion. The Wake Forest group, under the leadership of our18. Edwards MS, Craven BL, Stafford J, Craven TE, Sauve KJ, Ayerdi J,
et al. Distal embolic protection during renal artery angioplasty and
stenting. J Vasc Surg 2006;44:128-35.
19. Dean RH, Tribble RW, Hansen KJ, O’Neil E, Craven TE, Redding JF.
Evolution of renal insufficiency in ischemic nephropathy. Ann Surg
1991;213:446-55.
20. Marik PE, Varon J. Hypertensive crises: challenges and management.
Chest 2007;131:1949-62.
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more
accurate method to estimate glomerular filtration rate from serum
creatinine: a new prediction equation. Modification of Diet in Renal
Disease Study Group. Ann Intern Med 1999;130:461-70.
22. Hansen KJ, Tribble RW, Reavis SW, Canzanello VJ, Craven TE, Plonk
GW, Jr., et al. Renal duplex sonography: evaluation of clinical utility. J
Vasc Surg 1990;12:227-36.
23. Baumgartner I, von Aesch K, Do DD, Triller J, Birrer M, Mahler F.
Stent placement in ostial and nonostial atherosclerotic renal arterial
stenoses: a prospective follow-up study. Radiology 2000;216:498-505.
24. Henry M, Amor M, Henry I, Ethevenot G, Tzvetanov K, Courvoisier
A, et al. Stents in the treatment of renal artery stenosis: long-term
follow-up. J Endovasc Surg 1999;6:42-51.
25. Lederman RJ, Mendelsohn FO, Santos R, Phillips HR, Stack RS,
Crowley JJ. Primary renal artery stenting: characteristics and outcomes
after 363 procedures. Am Heart J 2001;142:314-23.
26. Tuttle KR, Chouinard RF, Webber JT, Dahlstrom LR, Short RA,
Henneberry KJ, et al. Treatment of atherosclerotic ostial renal artery
stenosis with the intravascular stent. Am J Kidney Dis 1998;32:611-22.
27. Zeller T, Frank U, Muller C, Burgelin K, Sinn L, Horn B, et al.
Stent-supported angioplasty of severe atherosclerotic renal artery steno-
sis preserves renal function and improves blood pressure control: long-
term results from a prospective registry of 456 lesions. J Endovasc Ther
2004;11:95-106.
28. Henry M, Klonaris C, Henry I, Tzetanov K, Le Borgne E, Foliguet B,
et al. Protected renal stenting with the PercuSurge GuardWire device: a
pilot study. J Endovasc Ther 2001;8:227-37.
29. Henry M, Henry I, Klonaris C, Polydorou A, Rath P, Lakshmi G, et al.
Renal angioplasty and stenting under protection: the way for the future?
Catheter Cardiovasc Interv 2003;60:299-312.
30. Holden A, Hill A. Renal angioplasty and stenting with distal protection
of the main renal artery in ischemic nephropathy: early experience. J
Vasc Surg 2003;38:962-8.
31. Holden A, Hill A, Jaff MR, Pilmore H. Renal artery stent revasculariza-
tion with embolic protection in patients with ischemic nephropathy.
Kidney Int 2006;70:948-55.
32. Cambria RP, Brewster DC, L’Italien GJ, Gertler JP, Abbott WM,
Lamuraglia GM, et al. Renal artery reconstruction for the preservation
of renal function. J Vasc Surg 1996;24:371-80.
33. Novick AC. Surgical revascularization for renal artery disease: current
status. BJU Int 2005;95 Suppl 2:75-7.
34. Arthurs Z, Starnes B, Cuadrado D, Sohn V, Cushner H, Andersen C.
Renal artery stenting slows the rate of renal function decline. J Vasc Surg
2007;45:726-31.
35. Mistry S, Ives N, Harding J, Fitzpatrick-Ellis K, Lipkin G, Kalra PA,
et al. Angioplasty and STent for Renal Artery Lesions (ASTRAL trial):
rationale, methods and results so far. J HumHypertens 2007;21:511-5.
36. Bax L, Mali WP, Buskens E, Koomans HA, Beutler JJ, Braam B, et al.
The benefit of STent placement and blood pressure and lipid-lowering
for the prevention of progression of renal dysfunction caused by Ath-
erosclerotic ostial stenosis of the Renal artery. The STAR-study: ratio-
nale and study design. J Nephrol 2003;16:807-12.Submitted Jan 16, 2008; accepted Apr 16, 2008.DISCUSSION
Dr William Bogey (Greenville, NC). I would like to thank the
association for the opportunity to discuss this paper, and Dr. Pearce
and colleagues for providing me with a copy of the manuscript in acurrent president, is well known for their expertise in the open
operative management of renovascular disease. This paper discusses
their experience with endovascular treatment of this disease process,
and, as we’ve come to expect, they have done an excellent job.
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September 2008588 Corriere et alEarly results were examined, and at a median of approximately
9weeks post procedure, statistically significant decreases in mean
systolic and diastolic BP as well as number of antihypertensive
meds were observed. When looked at categorically, however, only
approximately 22% had their hypertension helped, and 28% had
their renal insufficiency improved, while about 7% experienced a
worsening of renal function.
In reviewing this manuscript, a number of questions entered
my mind. I must confess, however, that many of these questions
were answered in the discussion section of the manuscript, and I
had to strike them from my list. Of course, I do still have a couple
of questions remaining. First, you note that previous experience
led you to the technical approach used. Can you enlighten us as to
the specifics of this technique? In particular, you feel that distal
protection is of value. My bias has been that the majority of
embolic debris that may damage the kidney is generated during the
process of gaining access to the artery, and thus by the time the
distal protection device has been deployed, the cat may well be out
of the bag. Do you feel differently, or does your technique allow
you to minimize this risk?
Secondly, you note that the results obtained here are better
when “complete” treatment is done, yet you also state that it is not
uncommon to perform only partial treatment in your current
algorithm. Will the results of this study cause you to alter this
algorithm?
Finally, you note that the magnitude of improvement follow-
ing percutaneous treatment is significantly less than that seen after
open therapy and you suggest that the trade-off in results versus
morbidity may be acceptable. My question is why is the magnitude
of improvement so much less? My admittedly naïve understanding
leads me to think that an open artery by any technique should give
a similar result, so why are the outcomes so dramatically different.
This study is only looking at short-term response, not the long-
term outcome that one might expect to favor surgery, eliminating
the bias improved long term durability might provide. It doesn’t
appear to me that it can all be explained by the lack of complete
treatment in the 21% in this study. Do you have any insight as to
why this may be? Is it continued microembolism from the diseased
aorta or renal artery, or perhaps the damage caused by the debris
that gets generated before the protection device is in place? Is it
that you are actually getting a less “complete” repair than your
ultrasound data would suggest, or is it perhaps some other factor?
Has the decreased morbidity caused you to expand your indica-
tions to include patients who would not have met your open repair
indications? I would appreciate your thoughts on this, as themagnitude of the difference in response between open and endo-
vascular repair shown by your group is indeed sobering.
Once again, I think the association for this opportunity, and I
look forward to hearing your response.
Dr. Pearce. Your first question involves the technical aspects
of distal embolic protection and why we continue to employ distal
protection. A paper presented last year at this meeting by Dr.
Corriere, categorized our embolic data from this procedure and
very nicely demonstrated the large amount of debris liberated by
angioplasty and stenting. Indeed you are correct that the previous
ex-vivo data demonstrated that just passing the guide wire results
in a large amount of embolic debris. We feel there is additional
benefit for catching the embolic debris that occurs with the angio-
plasty procedure itself.
Why are we still doing staged repair vs. complete intervention?
Our treatment algorithm involves treating patients with bilateral
disease in a unilateral fashion and then reassessing their response
including blood pressure control, hypertension medications uti-
lized, as well as renal function response. If the patient has an
adequate renal function and blood pressure response, we will
continue to maximize the medical management of atherosclerotic
risk factors and defer further intervention for observation. You
referred to the additional data and figure included in the paper. I
did not present that here because it confuses the issue a little. The
unadjusted results of the group as a whole suggested that patients
with bilateral disease undergoing bilateral repair favored better
than those undergoing unilateral repair. Unilateral repair of bilat-
eral disease was not common in this patient group and the results in
the figure are not adjusted for preoperative values. Moreover,
when a multivariable regression analysis was performed we did not
observe the same renal function benefits with complete vs. incom-
plete repair.
Your final question inquires as to why the results here less
favorable than those observed in our open repair experience? I
think that there are a number of factors that can play into that
observation, but this paper was not designed to provide a direct
comparison between open and percutaneous results. However,
when we compared the demographics of the patients in the percu-
taneous group to the demographics of the open group, we had
more diabetics in the percutaneous group. Additionally, the per-
cutaneous patients tended to be older by at least five years with less
renal insufficiency compared to the open group. Finally, I think
you have correctly mentioned additional factors that could also be
in play for the discrepancies in renal function response observed
which include the recognized residual disease and the effects of
embolization.
